2. Search Result
Search Result
Results for "

CBF

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Recombinant Proteins

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108470
    Ro5-3335
    3 Publications Verification

    		 Others Cancer
    Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation .
    Ro5-3335
  • HY-16786
    AI-10-49

    		Others Inflammation/Immunology Cancer
    AI-10-49 is an inhibitor of leukemic oncoprotein CBFβ-SMHHC. AI-10-49 inhibits the binding of CBFβ-SMMHCto the RUNX1 Runt domain with IC50 value of 0.26 μM. AI-10-49 can be used for the research of leukemia .
    AI-10-49
  • HY-16268
    Kartogenin
    Maximum Cited Publications
    20 Publications Verification

    KGN

    		 TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) is an inducer of differentiation of human mesenchymal stem cells into chondrocytes, with an EC50 of 100 nM. Kartogenin binds filamin A, disrupts its interaction with the transcription factor core-binding factor β subunit (CBFβ), and induces chondrogenesis by regulating the CBFβ-RUNX1 transcriptional program. Kartogenin can be used for the research of osteoarthritis (OA) .
    Kartogenin
  • HY-124137
    Runx1-CBFβ interaction inhibitor 1

    		Others Cancer
    Runx1-CBFβ interaction inhibitor 1 is an allosteric inhibitior of Runt domain-CBFb interaction (IC50=3.2 μM) .
    Runx1-CBFβ interaction inhibitor 1
  • HY-118365
    NSC 140873

    		Others Infection Cancer
    NSC 140873 is an inhibitor of the RUNX1-CBFβ interaction. NSC 140873 can be used for research of viral infection and leukemia. NSC 140873 has an unstable structure and can be converted spontaneously in solution to a benzodiazepine (Ro5-3335) .
    NSC 140873
  • HY-138617
    AI-10-47

    		Others Cancer
    AI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding, with an IC50 of 3.2 μM .
    AI-10-47
  • HY-A0168
    Regadenoson
    1 Publications Verification

    CVT-3146

    		 Adenosine Receptor Cardiovascular Disease
    Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS .
    Regadenoson
  • HY-146351
    HDAC-IN-38

    		HDAC Neurological Disease
    HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .
    HDAC-IN-38
  • HY-150014
    AMT-NHS

    		Others Others
    AMT-NHS is an RNA-protein crosslinker. AMT-NHS is composed of a psoralen derivative and an N-hydroxysuccinimide ester group which react with RNA bases and primary amines of protein, respectively. AMT-NHS can penetrate into living yeast cells and crosslink Cbf5 to H/ACA snoRNAs with high specificity. AMT-NHS induces different crosslinking patterns and targets both single- and double-stranded regions of RNA. AMT-NHS can be used for capturing diverse RNA-protein interactions in cells .
    AMT-NHS

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: